Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
Parkinson’s disease (PD) has long presented challenges in medication delivery. A staple in more advanced disease control, carbidopa-levodopa requires multiple daily dosing with supratherapeutic levels leading to dyskinesias and subtherapeutic concentrations leading to...
Doxepin is a tricyclic antidepressant first approved for the treatment of depression in 1969 by the FDA. Tricyclic antidepressants are famous for their anticholinergic adverse effects including sedation and have been replaced by better-tolerated medications as...
Technology continues to impact disease state management in remarkable ways. Monitoring of patients with diabetes is no exception. Both the American Diabetes Association and American Association of Clinical Endocrinologists/American College of Endocrinology make light...
Here’s a case scenario where the clinical outcome may have hinged on taking ziprasidone with or without food. KD is a 33-year-old male who was diagnosed with schizophrenia. Olanzapine and risperidone were the first antipsychotics that were tried to help...
